ScripAbeona Therapeutics obtained US Food and Drug Administration approval on 29 April for Zevaskyn, an autologous cell-based gene therapy for the ultra-rare connective tissue disorder recessive dystrophic
Pink SheetBeremagene geperpavec, Krystal Biotech’s topical gene therapy for the rare genetic skin disorder, dystrophic epidermolysis bullosa (DEB), is among the products that European Medicines Agency might thi
Pink SheetVyjuvek (beremagene geperpavec), Krystal Biotech’s topical gene therapy for the rare genetic skin disorder, dystrophic epidermolysis bullosa (DEB), could be approved for use across the EU soon, after
Pink SheetSeven new advanced therapy medicinal products (ATMPs) could be approved for pan-EU approval this year, based on data from the Pink Sheet’s EU regulatory filings tracker , including Roche / Sarepta